Todd Berard Sells 424 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard sold 424 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $25.46, for a total value of $10,795.04. Following the completion of the transaction, the chief marketing officer now owns 106,538 shares of the company’s stock, valued at $2,712,457.48. This represents a 0.40 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Todd Berard also recently made the following trade(s):

• On Wednesday, February 12th, Todd Berard sold 102 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total transaction of $2,707.08.
• On Monday, January 6th, Todd Berard sold 343 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total transaction of $9,267.86.

BioLife Solutions Stock Up 5.7 %

NASDAQ BLFS traded up $1.41 during trading on Wednesday, reaching $26.25. 502,346 shares of the company’s stock traded hands, compared to its average volume of 270,046. The company’s 50 day simple moving average is $26.67 and its two-hundred day simple moving average is $25.48. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -24.76 and a beta of 1.91. BioLife Solutions, Inc. has a 12-month low of $14.84 and a 12-month high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.32. The company had revenue of $22.71 million for the quarter, compared to the consensus estimate of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter in the prior year, the company earned ($0.21) EPS. As a group, sell-side analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Hedge Funds Weigh In On BioLife Solutions

A number of institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in BioLife Solutions in the fourth quarter valued at about $20,664,000. Massachusetts Financial Services Co. MA purchased a new stake in shares of BioLife Solutions in the 4th quarter valued at approximately $19,805,000. Point72 Asset Management L.P. acquired a new position in shares of BioLife Solutions in the 4th quarter worth approximately $11,113,000. Millennium Management LLC boosted its position in shares of BioLife Solutions by 49.1% during the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock worth $29,733,000 after purchasing an additional 377,111 shares during the period. Finally, Rockefeller Capital Management L.P. boosted its position in shares of BioLife Solutions by 81.3% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock worth $14,661,000 after purchasing an additional 262,504 shares during the period. 93.24% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BLFS has been the subject of several research analyst reports. KeyCorp raised their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Craig Hallum lifted their target price on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. TD Cowen increased their price target on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Benchmark restated a “buy” rating and set a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. Finally, HC Wainwright decreased their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, November 18th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.43.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.